Novel Compounds for the treatment of obesity

Reducing Body Weight and Glucose Levels  & Improving Cognitive Function

Novelty and IP Status

• The patent is covering Novel Active Compounds –derivatives of fatty acids and amino acids which may regulate feeding and body weight
• Compound X (the leading compound) and its derivatives represent novel compounds for the treatment of obesity which do not act on either CB1, TRPV1 or PPAR-α receptors (tested by MSD for receptor binding activity).
• The compounds present new mechanisms of action (via POMC, NPY or FAAH (Fatty Acid Amide Hydrolase) inhibition in relation to known compounds on the market: Xenical (Lipase inhibition), Reductil (NE-5HT re-uptake inhibitor) and Rimonobant (CB1 receptor antagonist) (removed recently from the market).
• They are made of natural products which may be given orally and act in a dose-dependent manner
• 3 compounds improve also cognitive function as well 3 compounds reduced glucose levels
• No toxicity was found following in vivo experiments in mice ,detecting survival, neurological score and liver histopathology
• There is a clear opportunity for  an effective and well-tolerated anti-obesity drugs. Weight loss continued for 31 days after cessation of treatment and then leveled off.

Key Features

• Patent on new compounds which are small natural, organic molecules
• Non toxic
• Can be delivered orally or by injection
• Effects resemble beneficial effects of moderate caloric restriction
• Reduce glucose blood levels
• Improve cognition

Development Milestones

• Continuing studies to determine optimal dosage levels and intervals
• Toxicology studies
• The effect on metabolic markers for diabetes and CVD

The Opportunity

• 1.1 billion people worldwide are suffering from the health consequences of overconsumption
• Only one drug is currently approved for long-treatment of obesity-the lipase inhibitor Xenical. Use of this product has been limited by side effects.

Patent Status

Granted US 9,428,448